http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110151775-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395 |
| filingDate | 2019-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110151775-B |
| titleOfInvention | Application of 17-DMAG in preparation of medicine for inhibiting acute lymphoblastic leukemia of children |
| abstract | The invention provides application of an Hsp90 inhibitor 17-DMAG in preparation of a medicine for inhibiting acute lymphoblastic leukemia of children, belonging to the technical field of medical biology. Experiments prove that the Hsp90 inhibitor 17-DMAG and cytarabine can synergistically promote the apoptosis of leukemia cells, but the Hsp90 inhibitor and daunorubicin and etoposide cannot achieve similar effects. The method provides a basis for establishing the reasonable application of the chemotherapy scheme of combining 17-DMAG and cytarabine in the children ALL chemotherapy, and provides possibility for improving the chemotherapy effect of leukemia patients and improving drug resistance; and the application of the 17-DMAG and the cytarabine as active ingredients in the children ALL in preparing the medicine for inhibiting the acute lymphoblastic leukemia of the children is proposed for the first time. |
| priorityDate | 2019-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.